Close

Coronavac

Serum neutralising activity against SARS-CoV-2 variants elicited by CoronaVac

Emergence of multiple SARS-CoV-2 variants of concern (VOCs) harbouring mutations in the spike protein—the major target of neutralising antibodies—has raised serious concerns about the potential for reduced protective efficacy of humoral responses elicited by vaccination. CoronaVac (Sinovac Biotech, Beijing, China) is an inactivated vaccine that has been authorised for conditional […]

Read More

Vacuna Coronavac

Si bien todas superan el 50% (y no llegan más allá del 92%), hay dudas respecto de la cantidad de personas que participan en los ensayos, y las fuentes que dan a conocer las tasas.  Días antes de que comience el lanzamiento mundial de la vacuna de Sinovac Biotech Ltd. […]

Read More